Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

The stock market has been on edge since the announcement of tariffs, reporting its biggest loss since March 2020. The damage ...